Race analysis in an African American sample with serious mental illness and comorbid diabetes

Abstract

Objectives: Targeted Training in Illness Management (TTIM) focuses on enhancing care engagement for people living with serious mental illness and diabetes. This secondary analysis from a 60-week, randomized controlled trial of TTIM versus treatment as usual evaluated racial subgroup outcomes.

Method: Demographics, clinical characteristics, and diabetes status were evaluated for those self-identifying as non-Hispanic White, African American, and Hispanic. Longitudinal response to TTIM was evaluated using a multiple domain risk index. Due to their small sample size; those identifying as Hispanic were excluded from this analysis.

Results: Non-Hispanic White participants had greater baseline socioeconomic advantages. Baseline risk scores, glycosylated hemoglobin (HbA1c) values, and HbA1c differences over time were similar for African American and non-Hispanic White participants.

Conclusions and implications for practice: African American participants living with serious mental illness and diabetes receiving TTIM did as well as non-Hispanic White participants. Inclusive approaches that feature peer support and are situated in safety-net health care settings need to be further investigated with respect to potentially impacting health disparities. (PsycINFO Database Record

Trial registration: ClinicalTrials.gov NCT01410357.

Conflict of interest statement

Declaration of Conflicting Interests:

Dr. Sajatovic has research grants from Pfizer, Merck, Janssen, Reuter Foundation, Woodruff Foundation, Reinberger Foundation, the National Institutes of Health (NIH), and the Centers for Disease Control and Prevention (CDC). Dr. Sajatovic is a consultant to Bracket, Prophase, Otsuka, Pfizer and Sunovion and has received royalties from Springer Press, Johns Hopkins University Press, Oxford Press, UpToDate, and Lexicomp.

Drs Dawson, McCormick, Bauer, Scheidenmantel and Gunzler have nothing to disclose. Ms. Howland has nothing to disclose.

(c) 2018 APA, all rights reserved).

Figures

Figure 1

Baseline risk index declines in a sample of individuals with SMI Comorbid.

Figure 2

Change in HbA1c from baseline to 30 weeks

Figure 3

Change HbA1c from baseline to 60 weeks